Oyster Point Pharma has enrolled the first patient in a phase 3 trial of OC-01, a nasal spray treatment candidate for the signs and symptoms of dry eye disease, according to a press release.
The multicenter, randomized, double-masked, placebo-controlled ONSET-2 clinical trial will evaluate the safety and efficacy of OC-01 in two doses, 0.6 mg/mL and 1.2 mg/mL, vs. placebo in 750 subjects at 20 U.S. centers.
“We believe OC-01 has the potential to change the way that eye care practitioners treat patients with dry eye disease due to the (Read more...)
Uncategorized